TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16707911
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) substitution therapy for 6 months
Study: 10486672
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (dihydropyridines, diltiazem, verapamil, bepridil)
Study: 10486672
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (subgroup analysis in patients over 65 years old)
Study: 10486672
Drug: Salicylates and
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylates and non-steroidal anti-inflammatory drugs
Study: 8610947
Drug: Amoxicillin, 500
Normalized name: Amoxicillin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 500 mg three times daily for 20 days
Study: 8610947
Drug: Azithromycin, 500
Normalized name: Azithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 500 mg once daily for 7 days
Study: 2023353
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B sulfate, neomycin sulfate, and vancomycin hydrochloride (PNV) administered six times daily in the oropharynx.
Study: 2023353
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered six times daily in the oropharynx.
Study: 6758744
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol (160 or 320 mg once daily)
Study: 6758744
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting propranolol (160 or 320 mg once daily)
Study: 24837493
Drug: NASHA Dx
Normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASHA Dx injection therapy
Study: 12237203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of segmental and extrasegmental stimulation
Study: 8821297
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment and cotton covers encasement
Study: 2074254
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 1 g cefodizime
Study: 2074254
Drug: Repeated intravenous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intravenous infusions of 1 g cefodizime twice daily for 4.5 days
Study: 7044069
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg or 150 mg/day)
Study: 7044069
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg or 150 mg/day)
Study: 30847828
Drug: Bupropion, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion, 150 mg twice daily
Study: 29630702
Drug: Varenicline, 1
Normalized name: Varenicline, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline, 1 mg twice daily
Study: 30847828
Drug: Nicotine patch,
Normalized name: Nicotine Patch, 7 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch, 21 mg/day with taper (active control)
Study: 29804407
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb761) drops oral treatment (3 times/d, 80 mg each time)
Study: 29804407
Drug: Routine oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oxygen inhalation and appeasement treatment
Study: 19282713
Drug: IVRA ketamine
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVRA ketamine (0.1 mg/kg in 1 mL of normal saline)
Study: 19282713
Drug: Systemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic ketamine (0.1 mg/kg in 1 mL of normal saline via peripheral IV)
Study: 17457158
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g intravenously every 8 hours for 7 to 21 days)
Study: 11050257
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge with home treatment supported by respiratory nurses
Study: 8923568
Drug: Mecamylamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (0, 10, or 20 mg)
Study: 1464339
Drug: Nisoldipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20 mg once a day for 4 weeks)
Study: 27349951
Drug: Topical 20%
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20% autologous serum eye drops (ASEs) with silicone-hydrogel soft contact lenses (SCLs)
Study: 19396774
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract associated with hyaluronic acid ophthalmic solution (GB‐HA)
Study: 19396774
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid ophthalmic solution (HA) alone
Study: 15829474
Drug: Original program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original program (specific to smokers in preparation stage)
Study: 15829474
Drug: Modified program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified program (specific to smokers in preparation stage)
Study: 10099052
Drug: Pidotimod (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (800 mg once a day for 90 days)
Study: 8088489
Drug: Ciprofloxacin 0.2
Normalized name: CIPROFLOXACIN 0.2/HC 1% OTIC SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 0.2 g intravenously b.i.d. + Metronidazole 0.5 g intravenously t.i.d.
Study: 8088489
Drug: Cefoxitin 2
Normalized name: cefoxitin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 2 g intravenously t.i.d. + Doxycycline 0.1 g b.i.d.
Study: 2031201
Drug: FAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC plus lonidamine (600 mg orally daily three times a day)
Study: 2031201
Drug: FAC (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC (standard therapy)
Study: 7016247
Drug: Fluorescent treponemal
Normalized name: treponemic skin canker preparation, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescent treponemal antibody‐absorption (FTA‐ABS) test
Study: 31131640
Drug: Somatic yoga
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatic yoga and meditation (SYM) intervention, twice a week for 8 weeks for 1.5 hours, with home program and journaling.
Study: 27815483
Drug: Artificial Tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial Tear (AT) therapy
Study: 24979446
Drug: Once‐daily oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐daily oral tenofovir disoproxil fumarate (TDF) or FTC‐TDF
Study: 24979446
Drug: Once‐daily oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐daily oral tenofovir-based PrEP
Study: 19270357
Drug: Isoflurane preconditioning
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane preconditioning (1.0 minimum alveolar concentration end-tidal, approximately 1.1% to 1.2%) administered for 30 min followed by a 15 min washout period before CPB.
Study: 19270357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no isoflurane inhalation).
Study: 17479540
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride extended-release (MXR) 1000 mg single dose
Study: 17479540
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride extended-release (MXR) 1000 mg/d for 9 days
Study: 17479540
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride immediate-release (MIR) 1000 mg single dose
Study: 17479540
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride immediate-release (MIR) 1000 mg/d for 14 days
Study: 8496328
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week for 1 year)
Study: 31230988
Drug: Movement System
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement System Impairment-Based classification treatment
Study: 28006108
Drug: Digitoxin 0.1
Normalized name: digitoxin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitoxin 0.1 mg daily for 28 days
Study: 28006108
Drug: Digitoxin 0.05
Normalized name: digitoxin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitoxin 0.05 mg daily for 28 days
Study: 21926600
Drug: Granulocyte-macrophage colony
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony stimulating factor (250 μg/M)
Study: 31361303
Drug: Pegvisomant therapy
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvisomant therapy
Study: 7933823
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (0.08 mg/kg)
Study: 3234411
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg (60 mg q.i.d.)
Study: 3234411
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg (100 mg b.i.d.)
Study: 2058318
Drug: Ketanserin (S2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (S2-receptor blocker) with concurrent physiotherapy
Study: 332188
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid combined with fentonium bromide (125 mg and 20 mg respectively, 3-4 capsules daily for 14 days)
Study: 31413691
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with irrigation and debridement
Study: 31413691
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with antibiotics and wound care
Study: 25026454
Drug: 5LEU (23/5/180/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5LEU (23/5/180/30 g of protein/leucine/carbohydrate/fat)
Study: 25026454
Drug: 15LEU (70/15/180/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15LEU (70/15/180/30 g of protein/leucine/carbohydrate/fat)
Study: 25026454
Drug: CON (0/0/274/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (0/0/274/30 g of carbohydrate/fat)
Study: 11551141
Drug: Calcium (CaCl2)
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (CaCl2) 15 mg/kg b.w. administered intravenously
Study: 11551141
Drug: Disodium EDTA
Normalized name: Disodium EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium EDTA 5 mg/kg b.w. administered intravenously
Study: 30374603
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D therapy
Study: 30374603
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment in children
Study: 28538134
Drug: Cannabidiol oral
Normalized name: cannabidiol Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day
Study: 23838836
Drug: Surgery-first approach
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery-first approach without presurgical orthodontic treatment
Study: 10439008
Drug: Sequential PCRs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential PCRs (group I, n = 30)
Study: 10439008
Drug: Primed in
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primed in situ labeling (PRINS) before five sequential PCRs (group II, n = 10)
Study: 10439008
Drug: Staining with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staining with hematoxylin before performing five sequential PCRs (group III, n = 11)
Study: 7995742
Drug: Cyclophosphamide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (120 mg/kg) and total body irradiation (1320 Gy in eight fractions over 4 days) (CY/TBI)
Study: 7995742
Drug: Busulfan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) (BU/CY)
Study: 31343196
Drug: Intensive Outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Outpatient Treatment (IOP)
Study: 29903423
Drug: xylazine and
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylazine and butorphanol administered intravenously (IV)
Study: 29903423
Drug: detomidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: detomidine and butorphanol administered IV
Study: 29903423
Drug: xylazine administered
Normalized name: Xylazine
DrugBank: Xylazine (DB11477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylazine administered IV and lidocaine topically
Study: 29903423
Drug: detomidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: detomidine administered IV and lidocaine topically
Study: 22918856
Drug: Test 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 250 mg metronidazole immediate release formulation
Study: 22918856
Drug: Reference 250
Normalized name: docusate
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference 250 mg metronidazole immediate release formulation
Study: 16136943
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment group (radiotherapy + Chinese herbal drugs)
Study: 7568433
Drug: Amiloride treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride treatment
Study: 1970907
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg plus Pseudoephedrine 60 mg
Study: 30824559
Drug: ODM‐101/65 (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM‐101/65 (65 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Study: 30824559
Drug: ODM‐101/105 (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM‐101/105 (105 mg carbidopa, 75-150 mg levodopa, 200 mg entacapone)
Study: 30824559
Drug: LCE (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCE (standard combination of 4:1 levodopa/carbidopa with 200 mg entacapone)
Study: 24092769
Drug: Calorie-matched low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-matched low carbohydrate diet (2.1 g·kg‐1)
Study: 17461874
Drug: Home orthostatic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home orthostatic self-training (daily sessions for 7 days a week for 4 weeks)
Study: 15932835
Drug: Bazedoxifene 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 2.5 mg/d
Study: 15932835
Drug: Bazedoxifene 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 5.0 mg/d
Study: 15932835
Drug: Bazedoxifene 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 30 mg/d
Study: 15932835
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg)/medroxyprogesterone acetate (2.5 mg) (active control)
Study: 11956508
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg bosentan twice a day for 10 days plus 2.5 mg glyburide twice a day on days 6 to 10
Study: 11956508
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg glyburide twice a day for 10 days plus 125 mg bosentan twice a day on days 6 to 10
Study: 1992536
Drug: 7‐3 (cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3 (cytarabine 100 mg/m2/d days 1 to 7 and daunorubicin 50 mg/m2/d days 1 to 3)
Study: 1992536
Drug: 7‐3‐7 (7‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3‐7 (7‐3 plus etoposide 75 mg/m2/d days 1 to 7)
Study: 6340300
Drug: Methylprednisolone 250
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 250 mg i.v. 2 hours before cis-platinum administration
Study: 27188899
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation at doses of 0.2, 0.4, 0.6, 0.8, or 1.0 mg daily for 6 weeks
Study: 27188899
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation at doses of 0.6 mg/d and above
Study: 23714686
Drug: Homeopathic syrup
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic syrup
Study: 22486138
Drug: Preoperative volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative volume loading (lactated Ringer 10 ml/kg before induction of general anesthesia)
Study: 16365696
Drug: Antioxidant supplemented
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplemented (90 days' diet supplementation with 500 mg/day vitamin E and 30 mg/day beta‐carotene, and the last 15 days also with 1 g/day vitamin C)
Study: 8363169
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of amikacin (20 mg/kg) and ceftriaxone (30 mg/kg for adults, 80 mg/kg for children)
Study: 8363169
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of amikacin (6.5 mg/kg every 8 hours) and ceftazidime (33 mg/kg every 8 hours)
Study: 8363169
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of amikacin and ceftriaxone
Study: 8363169
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of amikacin and ceftazidime
Study: 3539037
Drug: D-penicillamine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine therapy (DPA)
Study: 22868684
Drug: Nalfurafine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Nalfurafine (DB13471)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Nalfurafine hydrochloride (5 µg/day)
Study: 20358154
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) after failed MgSO4 therapy
Study: 20358154
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (MgSO4) after failed iNO therapy
Study: 18553228
Drug: S-1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 and docetaxel combination (Treatment Arm A)
Study: 18553228
Drug: S-1 only
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 only (Treatment Arm B)
Study: 12423984
Drug: Nitazoxanide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (100 mg twice daily orally for 3 days)
Study: 10712712
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with ketamine 0.5 mg.kg‐1
Study: 10712712
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with ketamine 0.5 mg.kg‐1
Study: 8626113
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (cisplatin and bleomycin)
Study: 8626113
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus whole pelvic radiation therapy (RT)
Study: 8626113
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (Chemotherapy alone and Chemotherapy plus RT)
Study: 1907963
Drug: Bupropion (225-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (225-450 mg/day)
Study: 31239200
Drug: Blephadex™ Eyelid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blephadex™ Eyelid Wipes (used on treated eyes once daily for 30 days)
Study: 27807617
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplements (ONS) administered until 12 weeks after discharge
Study: 26809652
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy with oral vinorelbine (60-80 mg/m² days 1 and 8) + cisplatin (80 mg/m² day 1) q3w
Study: 26809652
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy with oral vinorelbine and cisplatin
Study: 19916203
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alpha‐2b (1.5 microg/kg/week) and ribavirin (1000‐1200 mg/day orally)
Study: 15527186
Drug: No treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment, sham acupuncture, or standard treatment
Study: 11602811
Drug: Ciprofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate (100 mg/d)
Study: 11602811
Drug: Ciprofibrate +
Normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate + Aspirin (100 mg/d)
Study: 9838246
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement
Study: 8076919
Drug: Sham-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-therapy
Study: 31392337
Drug: 0.40 mg
Normalized name: Ascorbic Acid/Biotin/Calcium Pantothenate/Cyanocobalamin/Folic Acid/Niacinamide/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E 20 MG-0.05 MG-2.5 MG-0.001 MG-0.1 MG-4.5 MG-0.35 MG-0.40 MG-0.35 MG-1250 IU-200 IU-5 IU Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.40 mg Cr/kg diet (2× the approved level)